Leptin Antagonist Triple Mutant Ovine Recombinant, Pegylated

Lyophilized powder at room temperature.

Description: Pegylated Leptin Antagonist Triple Mutant Ovine Recombinant is a single non-glycosilated polypeptide chain containing 146 amino and additional Ala at N-terminus acids and having a molecular mass of ca. 35.6 kDa, Leptin was mutated, resulting in L39A/D40A/F41A mutant. However due to enlarged hydrodymanic volume it runs on the SGS-Page as 48 kDa protein and in gel-filtration on Superdex 200 as over 200kDa protein. Leptin Antagonist Triple Mutant Ovine Recombinant Mono-Pegylated with 20kDa PEG and was purified by proprietary chromatographic techniques.
Physical Appearance and Stability: Lyophilized Leptin Antagonist Triple Mutant Ovine Recombinant although stable at room temperature for several weeks, should be stored desiccated below -18¿C. Upon reconstitution at > 0.1 Lep-tA mutant mg/ml and up to 2mM and filter sterilization Leptin mutant can be stored at 4¿C or even room temperature for several weeks making it suitable for long term infusion studies using osmotic pumps. At lower concentration addition of a carrier protein (0.1% HSA or BSA) is suggested.
Please prevent freeze-thaw cycles.
Formulation and Purity: The protein was lyophilized from a concentrated (0.65mg/ml) solution with 0.003mM NaHCO3. Greater than 95.0% as determined by: (a) Gel filtration analysis. (b) Analysis by SDS-PAGE.
Solubility: It is recommended to reconstitute the lyophilized Leptin-Antagonist Triple Mutant Ovine Recombinant in sterile water or sterile 0.4% NaHCO3 adjusted to pH 8, not less than 100ug/ml, which can then be further diluted to other aqueous solutions.
Biological Activity: Pegylated triple antagonist is capable of inhibiting leptin-induced proliferation of BAF/3 cells stably transfected with the long form of human leptin receptor. Its in vitro activity is 6-8 fold lower than the non-pegylated antagonist but in vivo it has profound weight gain effect (as compared to the non-pegylated antagonist like in mouse leptin antagonists), resulting mainly from increased food intake.